top of page

GPCR Retreat Program

Targeting adenosine signaling for immuno-oncology

Targeting adenosine signaling for immuno-oncology

Date & Time

Friday, November 3rd / 4:35 PM


"Adenosine (ADO) signaling through A2A and A2B G protein-coupled receptors is increasingly recognized as an important immune checkpoint in the generation of anti-tumor immunity. Potent inhibitors of ADO signaling are currently being tested in cancer patients, including in randomized Phase 3 trial. I will present our recent work on adenosine-producing ectonucleotidases and adenosine signaling and discuss unexpected links between the adenosinergic pathway, DNA damage response and metabolic regulation."

Authors and Affiliations

John Stagg, David Allard.

Centre de Recherche du Centre Hospitalier de l'Université de Montréal; Faculté de Pharmacie. 900 St-Denis, Montréal, QC, H2X 0A9.

About John Stagg

"John Stagg is a Professor of Pharmacy at Université de Montréal and researcher at the CHUM Research Centre. Distinguished immunologist, Dr Stagg is recognized for having identified the adenosine-producing enzyme CD73 as a new cancer target, and for his translational work in immuno-oncology. Dr Stagg has served as an expert consultant in the development of adenosine-targeting drugs, several of which now in clinical trials. Dr Stagg is a member of the Board of Directors of BioCanRx, Canada's Immunotherapy Network, co-founder and permanent member of the Scientific Advisory Board (SAB) of Surface Oncology, a clinical stage company developing next generation immunotherapies, and member of the SAB of Domain Therapeutics, a biopharmaceutical company focused on GPCR in immuno-oncology."

John Stagg on the web

Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec

Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec

22nd GPCR Retreat Sponsored by


Canada Research Chairs
U of Ottawa
Canadian Institutes of Health Research
Bristol Myers Squibb
InversAgo Pharma
Monica Seger and Family
Duke University, Dept. Cell Biology
OHRI Neurosciences Program
University of Toronto Mississauga
Domain Therapeutics NA Inc.
Otsuka Pharmaceuticals
McGill University, Dept. Pharmacol & Exp Ther
University of Toronto, Dept. of Physiology
Hotchkiss Brain Institute,University of Calgary
Université de Montréal, VP Office
Find Therapeutics
University of Toronto, Dept. Pharmacol & Toxicol
Deep Apple
University of Illinois at Chicago (Mark Rasenick)
uOttawa, VP Research Office
American Society of Pharmacology and Experimental Therapeutics
University of Western Ontario Schulich School of Medicine & Dentistry
Université de Sherbrooke, Dept. Pharmacology-Physiology
Research Institute McGill Univ. Health Centre
adMare Bioinnovations
Université de Montréal, Faculty of Medicine
Université de Sherbrooke, Institut de Pharmacologie
Science Signaling
Montana Molecular
uOttawa, Dept. Cellular & Molecular Medicine
uOttawa, Dept. Biochem Microbiol Immunol
uOttawa, Behavioral & Physiology Core